1. Prognostic value of 18F‐FDG PET parameters in patients with locally advanced non‐small cell lung cancer treated with induction chemotherapy
- Author
-
Jae Kil Park, Sook Whan Sung, Hee Yeon Lee, Woo Hee Choi, Jin-Hyoung Kang, Ie Ryung Yoo, and Yeon Sil Kim
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Adenocarcinoma of Lung ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Fluorodeoxyglucose F18 ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Carcinoma ,Humans ,Clinical significance ,In patient ,030212 general & internal medicine ,Lung cancer ,Aged ,medicine.diagnostic_test ,business.industry ,Medical record ,Induction chemotherapy ,Induction Chemotherapy ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,Oncology ,Positron emission tomography ,Positron-Emission Tomography ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Lean body mass ,Female ,Neoplasm Recurrence, Local ,Radiopharmaceuticals ,business - Abstract
Aim To investigate predictive and prognostic role of metabolic parameters using [18 F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (18 F-FDG PET) in patients with locally advanced non-small cell lung cancer (NSCLC) treated with docetaxel-platinum induction chemotherapy (IC). Methods Medical records of 31 patients with pre- and post-IC 18 F-FDG PET were reviewed. Using 18 F-FDG PET, metabolic parameters, including metabolic tumor response, adjusted peak standardized uptake values using lean body mass at baseline (pre-SULpeak ) and after IC (post-SULpeak ), and percentage change of pre- and post-SULpeak (ΔSULpeak ), were assessed. Results Response rate (RR) was 71%, with a metabolic RR of 83.9%. Nineteen (61.3%) patients underwent surgery, R0 resection was achieved for 17 (89.5%) patients. Median relapse-free survival (RFS) and overall survival (OS) were 8.9 months (95% CI: 4.5-12.1) and 24.1 months (95% CI: 17.1-34.1), respectively. Post-SULpeak 1.4 could predict recurrence with a sensitivity of 84% and a specificity of 100%. Conclusion In patients with locally advanced NSCLC receiving IC, post-SULpeak and ΔSULpeak showed clinical significance for survival outcome.
- Published
- 2019
- Full Text
- View/download PDF